利培酮和奥氮平在难治性精神分裂症患者治疗中的应用效果对比分析
|
摘要
目的分析对比难治性精神分裂症采用利培酮和奥氮平的临床治疗效果。方法选取我院2017年1月至2018年1月收治的难治性精神分裂症患者68例,采用奇偶法分为研究组和参照组,每组各34例,参照组给予奥氮平治疗,研究组患者给予利培酮治疗,比较2组临床不良反应发生情况、治疗前后阴性症状、阳性症状以及一般病理评分。结果研究组不良反应总发生率5.88%低于参照组26.46%,组间对比具有显著性差异(P <0.05);2组治疗前阴性症状、阳性症状以及一般病理评分对比无显著性差异(P> 0.05),治疗后研究组评分低于参照组,组间对比统计学意义存在(P <0.05)。结论治疗难治性精神分裂症采用利培酮治疗效果优于奥氮平治疗效果,可全面改善患者临床症状,并且不良反应发生率也相对较低,其临床用药安全性较高。
Objective To analyze and compare the clinical efficacy of risperidone and olanzapine in the treatment of refractory schizophrenia. Methods Our hospital between January 2017 and January 2018, 68 cases of patients with refractory schizophrenia, using the parity method is divided into research group and control group, each group of 34 cases, control group given olanzapine treatment group patients give risperidone treatment, compared two groups of clinical adverse reaction happening, negative symptoms before and after the treatment, positive symptoms and general pathologic grading. Results The total incidence of adverse reactions in the study group was 5.88% lower than that in the reference group(26.46%). There was no significant difference in the negative symptoms, positive symptoms and general pathological scores of the two groups before treatment(P >0.05), and the score of the study group after treatment was lower than that of the reference group, with statistically significant difference between the two groups(P<0.05). Conclusion The treatment effect of risperidone is better than that of olanzapine in treating refractory schizophrenia, which can comprehensively improve the clinical symptoms of patients and the incidence of adverse reactions is relatively low.
Objective To analyze and compare the clinical efficacy of risperidone and olanzapine in the treatment of refractory schizophrenia. Methods Our hospital between January 2017 and January 2018, 68 cases of patients with refractory schizophrenia, using the parity method is divided into research group and control group, each group of 34 cases, control group given olanzapine treatment group patients give risperidone treatment, compared two groups of clinical adverse reaction happening, negative symptoms before and after the treatment, positive symptoms and general pathologic grading. Results The total incidence of adverse reactions in the study group was 5.88% lower than that in the reference group(26.46%). There was no significant difference in the negative symptoms, positive symptoms and general pathological scores of the two groups before treatment(P >0.05), and the score of the study group after treatment was lower than that of the reference group, with statistically significant difference between the two groups(P<0.05). Conclusion The treatment effect of risperidone is better than that of olanzapine in treating refractory schizophrenia, which can comprehensively improve the clinical symptoms of patients and the incidence of adverse reactions is relatively low.
引文
[1]彭国胜.利培酮和奥氮平在难治性精神分裂症患者治疗中的应用效果对比分析[J].当代医学,2018,24(13):106-107.
[2]曾义芝,吴林玲.利培酮和奥氮平在难治性精神分裂症患者治疗中的应用效果观察[J].医药前沿,2017,7(24):126.
[3]翟丽丽.利培酮和奥氮平在难治性精神分裂症患者治疗中的临床对比[J].中国卫生标准管理,2016,7(13):124-125.
[4]林天明,徐美娟.利培酮及奥氮平在难治性精神分裂症治疗中的对比分析[J].中国现代药物应用,2018,12(1):122-123.
[5]黄海涛.利培酮及奥氮平在难治性精神分裂症治疗中的对比研究[J].中国医药指南,2017,15(22):64.
[6]丁朝荣,张弟付.利培酮和奥氮平治疗难治性精神分裂症的疗效及对患者PANSS评分的影响[J].心理医生,2018,24(22):18-20.
[7]张文华.利培酮和奥氮平治疗难治性精神分裂症78例疗效对比[J].中国民康医学,2017,29(21):32-33.
[8]谢耀春.利培酮和奥氮平治疗难治性精神分裂症的疗效与安全性[J].临床合理用药杂志,2016,9(20):55-56.
[9]宋舟.奥氮平治疗难治性精神分裂症效果分析[J].基层医学论坛,2015,19(33):4655-4656.
[10]覃电泽,周芳珍,石广念.奥氮平联合利培酮治疗难治性精神分裂症的疗效观察[J].内科,2018,13(1):61-63.
[2]曾义芝,吴林玲.利培酮和奥氮平在难治性精神分裂症患者治疗中的应用效果观察[J].医药前沿,2017,7(24):126.
[3]翟丽丽.利培酮和奥氮平在难治性精神分裂症患者治疗中的临床对比[J].中国卫生标准管理,2016,7(13):124-125.
[4]林天明,徐美娟.利培酮及奥氮平在难治性精神分裂症治疗中的对比分析[J].中国现代药物应用,2018,12(1):122-123.
[5]黄海涛.利培酮及奥氮平在难治性精神分裂症治疗中的对比研究[J].中国医药指南,2017,15(22):64.
[6]丁朝荣,张弟付.利培酮和奥氮平治疗难治性精神分裂症的疗效及对患者PANSS评分的影响[J].心理医生,2018,24(22):18-20.
[7]张文华.利培酮和奥氮平治疗难治性精神分裂症78例疗效对比[J].中国民康医学,2017,29(21):32-33.
[8]谢耀春.利培酮和奥氮平治疗难治性精神分裂症的疗效与安全性[J].临床合理用药杂志,2016,9(20):55-56.
[9]宋舟.奥氮平治疗难治性精神分裂症效果分析[J].基层医学论坛,2015,19(33):4655-4656.
[10]覃电泽,周芳珍,石广念.奥氮平联合利培酮治疗难治性精神分裂症的疗效观察[J].内科,2018,13(1):61-63.